Cardlytics (NASDAQ:CDLX) Price Target Cut to $12.00

Cardlytics (NASDAQ:CDLX - Free Report) had its price objective reduced by Craig Hallum from $18.00 to $12.00 in a research report sent to investors on Thursday, Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts have also issued reports about the stock. Lake Street Capital boosted their price target on shares of Cardlytics from $13.00 to $18.00 and gave the company a buy rating in a research report on Friday, March 15th. Needham & Company LLC reduced their price target on shares of Cardlytics from $17.00 to $12.00 and set a buy rating on the stock in a research report on Thursday.

Cardlytics Price Performance

Shares of Cardlytics stock traded down $5.33 during trading on Thursday, hitting $9.27. 9,158,153 shares of the company's stock traded hands, compared to its average volume of 1,551,453. The company has a debt-to-equity ratio of 1.91, a current ratio of 1.31 and a quick ratio of 1.31. The firm's fifty day moving average price is $12.51 and its 200 day moving average price is $9.74. Cardlytics has a twelve month low of $4.94 and a twelve month high of $20.52. The company has a market cap of $446.57 million, a PE ratio of -2.52 and a beta of 1.50.

Cardlytics (NASDAQ:CDLX - Get Free Report) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.14) EPS for the quarter. The firm had revenue of $89.17 million during the quarter. Cardlytics had a negative net margin of 43.56% and a negative return on equity of 25.38%.

Insider Transactions at Cardlytics

In other news, COO Amit Gupta sold 23,416 shares of the company's stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $11.91, for a total transaction of $278,884.56. Following the transaction, the chief operating officer now directly owns 122,676 shares in the company, valued at $1,461,071.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Nicholas Hollmeyer Lynton sold 12,460 shares of the business's stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $13.69, for a total transaction of $170,577.40. Following the completion of the sale, the insider now directly owns 71,355 shares of the company's stock, valued at $976,849.95. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Amit Gupta sold 23,416 shares of the business's stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $11.91, for a total transaction of $278,884.56. Following the sale, the chief operating officer now directly owns 122,676 shares of the company's stock, valued at $1,461,071.16. The disclosure for this sale can be found here. Over the last three months, insiders have sold 36,306 shares of company stock worth $455,203. Corporate insiders own 4.40% of the company's stock.

Institutional Investors Weigh In On Cardlytics

Institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its stake in Cardlytics by 349.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,602 shares of the company's stock valued at $88,000 after purchasing an additional 7,465 shares in the last quarter. D L Carlson Investment Group Inc. bought a new stake in Cardlytics in the third quarter valued at approximately $173,000. SG Americas Securities LLC increased its stake in Cardlytics by 34.3% in the fourth quarter. SG Americas Securities LLC now owns 21,461 shares of the company's stock valued at $198,000 after purchasing an additional 5,484 shares in the last quarter. Clear Street Markets LLC bought a new stake in Cardlytics in the fourth quarter valued at approximately $199,000. Finally, Check Capital Management Inc. CA increased its stake in Cardlytics by 14.0% in the fourth quarter. Check Capital Management Inc. CA now owns 23,200 shares of the company's stock valued at $214,000 after purchasing an additional 2,850 shares in the last quarter. 68.10% of the stock is owned by institutional investors.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.